Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion

Therapeutic antibodies sometimes elicit anti-drug antibodies (ADAs) that can affect efficacy and safety. Engineered antibodies that contain artificial amino acid sequences are potentially highly immunogenic, but this is currently difficult to predict. Therefore, it is important to efficiently assess...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshiyuki Arata, Shigeki Motoyama, Mariko Yano, Tatsuya Ikuno, Shunsuke Ito, Tomochika Matsushita, Akira Takeiri, Yukari Nishito, Nami Yabuki, Hideaki Mizuno, Zenjiro Sampei, Masayuki Mishima, Masaki Honda, Jumpei Kiyokawa, Hiromi Suzuki, Shuichi Chiba, Mitsuyasu Tabo, Chiyomi Kubo
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
Anti-drug antibody
antibody engineering
biotherapeutics
IL-2
immunogenicity
PBMC
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2253570
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2253570

Similar Items